NEW YORK ( TheStreet) -- Geron Corporation (Nasdaq: GERN) hit a new 52-week low Thursday as it is currently trading at $1.58, below its previous 52-week low of $1.59 with 841,713 shares traded as of 11:10 a.m. ET. Average volume has been 1.6 million shares over the past 30 days.

Geron has a market cap of $230.1 million and is part of the health care sector and drugs industry. Shares are down 68.8% year to date as of the close of trading on Wednesday.

Geron Corporation, a biopharmaceutical company, develops biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes.
  • Practice your GERN trading strategies and win cash in our stock game.

TheStreet Ratings rates Geron as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. You can view the full Geron Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.

If you liked this article you might like

Geron Shares Take a Dive After J&J Unit-Led Trial Falters; Endo Closes Higher: Biotech Movers

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

Biotech Premarket Movers: Innoviva, Akebia, Geron

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Geron (GERN) Stock Rises on $80 Million Janssen Licensing Deal